Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
Roger von Moos(Kantonsspital Graubünden), Karen Chung(Viking Therapeutics (United States)), Charles S. Cleeland(The University of Texas MD Anderson Cancer Center), Danail Damyanov(National Specialized Hospital for Active Treatment of Hematologic Diseases), Janet E. Brown(University of Sheffield), Donald L. Patrick(Donaldson (United States)), Gavin Marx, Blair Egerdie(Urology Associates), Lesley Fallowfield(Brighton and Sussex Medical School), Yi Qian(Amgen (United States)), Jean-Jacques Body(National Cancer Centre Japan), Alison Stopeck(National Cancer Centre Japan), Ada Braun(National Cancer Centre Japan), Felipe Palazzo
Cited by 94
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k